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Abstract: 
Although organophosphate (OP)-induced acetylcholinesterase (AChE) inhibition is the critical 
mechanism causing toxicities that follow exposure, other biochemical events, including oxidative 
stress, have been reported to contribute to OP toxicity. Fullerenes are carbon spheres with 
antioxidant activity. Thus, we hypothesized that fullerenes could counteract the effects of OP 
compounds and tested this hypothesis using two in vitro test systems, hen brain and human 
neuroblastoma SH-SY5Y cells. Cells were incubated with eight different derivatized fullerene 
compounds before challenge with paraoxon (0 = control, 5 × 10−8, 10−7, 2 × 10−7 or 5 × 10−
7 M) or diisopropylphosphorofluoridate (DFP, 0 = control, 5 × 10−6, 10−5, 2 × 10−5, and 5 × 10−
5 M) and measurement of AChE activities. Activities of brain and SH-SY5Y AChE with OP 
compounds alone ranged from 55–83% lower than non-treated controls after paraoxon and from 
60–92% lower than non-treated controls after DFP. Most incubations containing 1 and 10 μM 
fullerene derivatives brought AChE activity closer to untreated controls, with improvements in 
AChE activity often >20%. Using dissipation of superoxide anion radicals as an indicator 
(xanthine oxidation as a positive control), all fullerene derivatives demonstrated significant 
antioxidant capability in neuroblastoma cells at 1 μM concentrations. No fullerene derivative at 
1 μM significantly affected neuroblastoma cell viability, when determined using either Alamar 
Blue dye retention or a luminescent assay for ATP production. These studies suggest that 
derivatized fullerene nanomaterials have potential capability to ameliorate OP-induced AChE 
inhibition resulting in toxicities. 
 Fullerenes | Organophosphates | Acetylcholinesterase inhibition Keywords:
Article: 
1. Introduction 
Organophosphorus (OP) compounds are widely used as insecticides, but they also represent a 
class of extremely potent chemical warfare agents that can cause incapacitation and death within 
minutes of exposure (ATSDR, 2006). Their critical mechanism of action is inhibition of 
acetylcholinesterase (AChE), which is followed by cholinergic poisoning. In addition, rapid 
AChE inhibition occurring after OP exposure has been reported to result in oxidative stress, as 
indicated by reduction in glutathione, increases in reactive oxygen species (ROS), and 
production of stress proteins (Giordano et al., 2006, Jett and Narova, 2000,Pazdernik et al., 
2001 and Qiao et al., 2005). Current medical measures against OP toxicoses are atropine, which 
blocks muscarinic cholinergic receptors, and oxime reactivators, which can remove OP 
compounds from AChE. The latter compounds are only effective, however, if they are given 
before the OP compound essentially irreversibly binds to this enzyme. Other treatments are 
symptomatic and supportive (ATSDR, 2006) and do not specifically target noncholinergic 
effects associated with OP toxicoses. 
Because OP agents can be very toxic and treatments are relatively limited, we initiated 
experiments to examine a new type of agent that has the potential to improve treatment when 
such exposures occur. The rationale for these studies was based on two observations. First, OP-
induced toxicity can have an oxidative stress component (Giordano et al., 2006, Pazdernik et al., 
2001 and Qiao et al., 2005). Second, fullerenes are potent antioxidants that have been referred to 
as free radical “sponges’ (Ali et al., 2008, Dugan et al., 1996, Johnson et al., 2010 and Wang et 
al., 1999). Since fullerenes without derivation are water insoluble we used addition chemistry to 
chemically attach various moieties to C60, C70, and C80 fullerene cages to make them compatible 
with biological systems (Iezzi et al., 2002, Johnson et al., 2010, Lee et al., 2002, Olmstead et al., 
2001, Wang et al., 1999 and Yin et al., 2006). Whereas native fullerenes produce aggregates in 
water that are cytotoxic to cultured cells, water soluble fullerenes are generally non-cytotoxic 
(Isakovic et al., 2006 and Sayes et al., 2004). 
The present in vitro study was conducted to screen a series of derivatized fullerenes:(1) for their 
capability to protect AChE derived from two different sources (hen brain and human 
neuroblastoma cells), (2) to determine if these fullerene derivatives could have added benefit as 
antioxidants, and (3) to evaluate their safety by examining their ability to affect cell viability. In 
addition, in vitro studies aid selection of doses that could be useful for in vivo studies 
( ICCVAM, 2008). Initial testing in vitro is especially valuable when studying effects of OP 
compounds, as their primary toxic mechanism (AChE inhibition) can be easily and reliably 
examined in non-animal systems ( Ehrich et al., 1997). 
2. Materials and methods 
2.1. Fullerenes 
A total of eight derivatized empty cage or metallo-fullerene compounds were tested, including 
two hydroxylated C60 (C60–OH) (one commercially available at BuckyUSA Inc., and one made 
and characterized at Luna nanoWorks), carboxylated C60 (C60–COOH), C60–pyrrolidine (C60–
PRD), hydroxylated C70 (C70–OH), C70–tetraglycolic acid (C70–TGA), hydroxylated scandium 
Trimetaspheres™ (Sc3N@C80–OH), and hydroxylated gadolinium Trimetaspheres™ (Gd3N@C80–
OH). All were provided by Luna Innovations Incorporated, Blacksburg, VA. The C60–OH, C60–
COOH, and C60–PRD were purchased from BuckyUSA Inc. (Houston, TX). Those synthesized 
by Luna nanoWorks, Danville, VA, included a C60–OH, C70–OH, C70–TGA, Sc3N@C80–OH and 
Gd3N@C80–OH. Hydroxylated fullerenes were synthesized as described (Husebo et al., 2004). In 
brief, pristine (without moieties added to the carbon cage) empty cage or metallo fullerenes (C60, 
C70, Sc3N@C80, and Gd3N@C80) were suspended in anhydrous dichloromethane under nitrogen 
atmosphere and 30 equivalents of potassium superoxide (KO2) and catalytic amounts of 18-
crown-6 were added to the suspension and stirred for two hours at room temperature. After the 
reaction was completed, derivatized fullerenes were precipitated, the organic layer decanted, and 
the fullerene materials were washed three times with dichloromethane to remove residual 18-
crown-6. A small volume of distilled water was added to dissolve the fullerene materials leading 
to a dark brown solution of hydroxylated fullerenes, which was then purified via a combination 
of size exclusion chromatography (Sephadex G-25 column) and dialysis (2000 Da MW cut-off). 
The purity of hydroxylated fullerenes was evaluated by reverse phase TLC as >95%. The carbon 
cages in hydroxylated fullerenes were functionalized with hydroxyl groups (∼20 hydroxyls per 
molecule) as demonstrated by Fourier transform infrared (FTIR) spectroscopy and 
thermogravimetric analysis. C70–TGA (4 glycolic acids attached to the cage with two acids at 
each pole of the oval-shaped C70 molecule) was synthesized through the Bingel–Hirsch reaction 
as follows: C70 was reacted with two equivalents of di(tert-butylglycolate)malonate in the 
presence of non-nucleophilic weak base DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) and 
alkylating reagent iodine in toluene under nitrogen atmosphere for four hours at room 
temperature (Zhou et al., 2003). The product was isolated and purified with silica 
chromatography to yield the tert-butyl ester precursor of C70–TGA. Trifluoroacetic acid 
deprotection of the tert-butyl esters in dichloromethane resulted in C70–TGA, which was 
characterized by nuclear magnetic resonance (NMR) and matrix assisted laser 
desorption/ionization mass spectrometry (MALDI-MS) and its purity (>95%) was assessed by 
HPLC. The molecular size of the synthesized fullerene compounds is 1–2 nm depending on the 
side groups attached to the carbon cage. However, these materials form aggregates in aqueous 
media and DLS (dynamic light scattering) shows the aggregate size of 20–50 nm for C70–TGA in 
phosphate buffered saline (PBS) and 50–100 nm for hydroxylated fullerenes at concentrations 
tested in phosphate buffered saline (PBS). The lipophilicity increases in the following order: 
hydroxylated fullerenes, carboxylated fullerenes, C60–PRD and C70–TGA. 
2.2. Organophosphorus test agents 
Paraoxon and diisopropylphosphoroflouridate (DFP) were obtained from Chem Services, West 
Chester, PA, and Aldrich Chemical Co., St. Louis, MO, respectively. Suppliers’ information 
noted purities >98%. They were prepared in a chemical safety hood as 0.1 M solutions in ethanol 
vehicle and diluted with phosphate buffer (0.1 M, pH 7.4) immediately before incubations 
following standard operating procedures of Virginia-Maryland Regional College of Veterinary 
Medicine for handling of laboratory chemicals. 
2.3. Assays for cytotoxicity 
Cytotoxicity of the eight fullerene derivative test agents was examined in primary murine 
neuronal cultures and human neuroblastoma cells using a cellular luminescence assay for ATP 
production (Promega Cell Titer-Glow® assay kit, San Francisco, CA, USA). The cells were 
seeded at concentrations of 20,000 (mouse cortex) or 5400 (human neuroblastoma) cells per well 
in 96-well opaque plates overnight and treated with 0, 1, 10 and 100 μM concentrations of 
fullerenes for 24 h. Control optical density values (mean ± SD) were 1285 ± 60 and 
17183 ± 2975 pixels, respectively. Human neuroblastoma cells were also tested with the same 
concentrations of fullerene derivatives using the Alamar Blue assay (Ehrich and Sharova, 2000). 
This assay compares fluorescence (excitation 530 nm; emission 590 nm) of a water soluble dye 
in cultures of treated cells with fluorescence in cultures of vehicle-treated cells after 24 h of 
treatment. Optical densities of controls were 4151 ± 941 pixels. Ethanol (10%) was used as a 
positive control. Lack of cytotoxicity to neuroblastoma cells of the organophosphorus test 
compounds used for this study was previously determined and reported (Ehrich et al., 1997). 
2.4. Fullerene derivatives antioxidant capability 
A xanthine/xanthine oxidase system was used to generate superoxide free radical to measure the 
superoxide-scavenging activity of fullerene derivatives as described (Li et al., 1998). This well-
established in vitro system is biologically relevant as it produces the reactive oxygen species 
involved in cell injury. The reaction mixture, kept at 37 °C, contained 1.0 ml of 50 mM 
phosphate buffered saline (PBS), pH 7.4, 270 μM xanthine, and 3.27 mU/ml xanthine oxidase 
in the absence or presence of various concentrations of fullerene derivatives prepared in PBS. 
Lucigenin (10 μM) was added to the reaction mixture and chemiluminescence was monitored 
over a 30 min period with a tube luminometer (AutoLumat LB 953, Berthold Technologies, Bad 
Wildbad, Germany). Integrated area under the curve was calculated and values compared 
between reaction mixtures of the positive control (incubates without fullerenes) and the 
fullerene-containing reaction mixtures. Numbers for positive control incubates over the series of 
experiments ranged from 41,740 to 70,536. Data from each assay were individually converted to 
percent of control for depiction in this manuscript. Inability of the fullerene derivatives to affect 
capability to produce uric acid was used to identify the action of the fullerene derivative as a 
scavenger of the free radicals rather than a xanthine oxidase enzyme inhibitor ( Li et al., 1998). 
2.5. AChE enzyme sources and AChE assay 
Brains were obtained from adult hens, Department of Animal and Poultry Science, Virginia 
Tech. Human neuroblastoma cells (SH-SY5Y) were obtained from the American Type Culture 
Collection (ATCC), Manassas, VA, and cultured to prepare retinoic acid-differentiated cells as 
reported previously (Ehrich et al., 1997). Embryronic day 18 mouse cerebral cortices were 
obtained from BrainBits LLC, Springfield, IL, and cultured to create a primary neuronal culture 
following the supplier’s protocol. AChE activity was measured spectrophotometrically using a 
colorimetric microtiter assay previously described (Correll and Ehrich, 1991). 
Organophosphorus compound (or an equivalent volume of vehicle) and fullerene derivatives 
were pre-incubated for 15 min at room temperature before addition to the wells of a 96-well plate 
that contained 0.048 mg of hen brain homogenate or 500,000 neuroblastoma cells. The reaction 
was initiated with addition of the acetylthiocholine substrate, and the yellow product of its 
hydrolysis was measured at 412 nm after 30 min at 28 °C. Optical density changes in controls 
were 0.921 ± 0.324 (mean ± SD, n = 30) with 500,000 cells/well and 1.494 ± 0.440 (n = 40) 
with 0.05 mg hen brain. Each fullerene derivative was tested against each concentration of OP 
compound and each concentration of fullerene with a minimum of three different batches of cells 
or homogenates. 
2.6. Statistical analyses 
Quantitative results from cytotoxicity determinations, acetylcholinesterase assays, and 
antioxidant capability were expressed as mean ± SE) of three or more assays using different 
batches of cells or hen brain homogenates. Subsequently, for each combination of in vitro test 
system (brain or SH-SY5Y cells), OP compound (paraoxon or DFF), and fullerene (two C60–OH 
compounds, C60–COOH, C60–PRD, C70–OH, C70–TGA, Sc3N@C80–OH and Gd3N@C80–OH), 
the fullerene control concentration of 0 M was compared to the other 3 concentrations (1, 10 and 
100 μM) using ANOVA followed by Dunnett’s procedure for multiple comparisons. Residual 
plots were inspected to verify model adequacy (i.e., that the errors followed a normal distribution 
with a constant variance). Statistical significance was set to alpha = 0.05. All analyses were 
performed using SAS version 9.2 (Cary, NC, USA). 
3. Results 
3.1. Fullerene cytotoxicity 
Primary neuronal cells from mouse brain were more sensitive to fullerene derivative-induced 
decreases in ATP production detected by change in luminescence than human neuroblastoma 
cells (Fig. 1A and B). The highest concentration tested (100 μM) of all eight test derivatives, 
except C60–COOH, significantly affected the primary neuronal cells (Fig. 1A), but not all of 
derivatives had the same detrimental effect on the neuroblastoma cells at this concentration (Fig. 
1B). Also, no notable cytotoxicity to the neuroblastoma cells was seen with 10 μM of any 
fullerene derivatives, whereas Sc3N@C80–OH significantly decreased ATP production in the 
primary neuronal cells. When viability was determined using the Alamar Blue assay (Fig. 1C), 
none of the fullerene-challenged cells were affected with any of the concentrations of the test 
fullerene derivatives (1, 10 or 100 μM, although not all concentrations were tested with some). 
The Alamar Blue assay could not be used with the primary murine cells due to interference of 
their medium with the assay reagents. 
 
Fig. 1. Fullerene derivatives had limited cytotoxic effects after 24 h of exposure. Viability is expressed as 
luminescent indication of ATP production in primary murine cells (A) and human neuroblastoma SH-
SY5Y cells (B) and as Alamar Blue retention in neuroblastoma calls (C). Each fullerene derivative was 
tested with a minimum of three different batches of cells, with results expressed as mean ± SE. Viability 
of vehicle-treated cells (controls) was >94% with every batch of cells with variability too low to illustrate 
when the neuroblastoma cells were used. Ethanol 10% was used as a positive control, providing viability 
of <5% in all systems. At 10 μM concentrations, only Sc3N@C80–OH caused any significant detrimental 
effects, and these effects were only seen with the primary cultures. When 100 μM fullerenes were used, 
all but C60–COOH caused significant decrease in ATP production in primary murine neuronal cells and 
five of eight fullerene derivatives had significant effects on the ATP production in human neuroblastoma 
cells. No fullerene derivative at any test concentration affected Alamar Blue retention (commercial C60–
OH and C60–COOH were not tested at all concentrations). 
3.2. Antioxidant capability of the fullerenes derivatives 
All fullerene derivatives tested at 10 μM were able to scavenge free radicals formed from 
xanthine by xanthine oxidase. This effect was concentration dependent (Fig. 2). All but the 
commercial C60–OH had capability to do so at 1 μM also, and C70–TGA, Sc3N@C80–OH, and 
Luna’s C60–OH were effective at 0.1 μM as well. All but C70–OH and Luna’s C60–OH of the 
fullerene derivatives were examined for their effectiveness as antioxidants at 0.01 and 0.001 μ
M, with no significant protective effect (data not shown). The lack of effects on xanthine oxidase 
indicated that the effect of the fullerene derivatives was to scavenge free radicals, not to interfere 
with their production (data not shown). 
 
Fig. 2. Free radical scavenging capability of fullerene derivatives. A xanthine/xanthine oxidase system 
was used as a generating system, with xanthine providing the positive control. Results are presented as 
mean ± SE, n > 3. Antioxidant effects, as indicated by bars lower than that of the xanthine control, were 
significant (p < 0.05) at 1 μm and 10 μM except with the commercial C60–OH at 1 μM (second triplet 
of bars). C70–TGA, Sc3N@C80–OH, C70–OH, and Luna’s C60–OH (last triplet of bars) were also effective 
antioxidants at 0.1 μM. 
3.3. Decreased OP-induced AChE inhibition in the presence of fullerenes derivatives 
Inclusion of the eight derivatized fullerene test compounds in incubates containing paraoxon or 
DFP with AChE of human neuroblastoma cells and hen brain homogenates generally indicated a 
protective effect of the fullerene derivatives against OP-induced AChE inhibition (Fig. 3). The 
fullerene derivatives alone did not affect AChE determinations, with the exception of 100 μM 
C70–TGA, which reduced activity to 70% of control in neuroblastoma cells and 21% of control in 
hen brain homogenates (data not shown). The capability of fullerene derivatives to decrease OP-
induced AChE inhibition was indicated by higher AChE activities in incubates containing the 
fullerene derivative than in incubates in which they were lacking. Fig. 3 shows results with only 
one of the four concentrations of OP compounds used for testing and the lowest concentration 
(1 μM) of fullerene derivative used for routine screening. Ten- and 100-fold higher 
concentrations of the fullerene derivatives were not significantly better protectants than 1 μM 
(Fig. 4A). The effectiveness of the fullerenes, as indicated by differences in AChE activities in 
their presence, was generally greater with AChE in hen brain homogenates and generally 
extended over all but the highest OP concentrations tested (5 × 10−7 M for paraoxon and 5 × 10
−5 M for DFP, Fig. 4B) for this enzyme source. For example, using both p < 0.05 and >20% 
improvement in AChE activity as indicators of effectiveness, all fullerene derivatives at 
concentrations of 1 and 10 μM resulted in increased hen brain AChE activity after 5 × 10−8 M 
paraoxon or 5 × 10−6 M DFP whereas none met this criteria against 5 × 10−7 M paraoxon or 
5 × 10−5 M DFP. At these higher OP concentrations, AChE activity in the absence of the 
fullerene derivatives was <20% of control. All but C70–TGA provided significant improvement 
of AChE activity against multiple concentrations of both paraoxon and DFP when hen brain 
homogenates were used. Fullerene derivatives that demonstrated the most effectiveness against 
paraoxon and DFP in neuroblastoma cells were C60–COOH, Sc3N@C80–OH, and C70–OH. 
  
Fig. 3.  Comparison of AChE activity in human neuroblastoma SH-SY5Y cells and hen brain 
homogenates treated with paraoxon or DFP in the absence and presence of 1 μM fullerene derivatives. 
Paraoxon or DFP were incubated with the fullerene derivative (or vehicle) for 15 min before addition to 
incubates containing the neuronal cells or brain homogenates. Results are presented as mean ± SE of >3 
different assays. Results with commercial C60–OH are in the second triplet of columns and results with 
C60–OH made by Luna nanoWorks are provided in the last triplet of columns. For (A) (neuronal cells), 
significant differences (p < 0.05) between cell AChE activity after paraoxon in the absence and presence 
of fullerenes were noted for Gd3N@C80–OH, C60–COOH, and Sc3N@C80–OH. For (B), and (D) (brain 
homogenates), differences in brain AChE after paraoxon were noted when all fullerene derivatives were 
included in the incubates. For (C) (neuronal cells), differences in cell AChE after DFP were noted for all 
but C60–PRD. 
 
Fig. 4. Comparison of the effectiveness of 1 and 10 μM fullerene derivative concentrations when 
protecting human neuroblastoma cells and hen brain homogenates from C60–COOH, Sc3N@C80–OH, and 
C70–OH. (A) demonstrates that increasing the fullerene derivative concentration from 1 to 10 μM did not 
significantly affect changes in AChE activity. (B) demonstrates differences in fullerene derivative 
effectiveness against paraoxon and DFP-induced AChE inhibition in neuroblastoma cells and hen brain 
homogenates, noting that fullerenes had similar effects in cells and brain homogenates, and that greater 
benefit was seen when concentrations of the OP compounds were lower. Improvement was significant 
(p < 0.05) for all cases demonstrated in Fig. 4. 
As 1 μM fullerenes appeared effective against 10−7 and 5 × 10−8 M paraoxon-induced AChE 
inhibition in hen brain homogenates, further testing with these paraoxon concentrations with 
lower concentrations of Gd3N@C80–OH, commercial C60–OH, and C70–TGA was done. 
Capability to keep AChE activity >20% higher than in incubates with 5 × 10−8 M paraoxon 
alone was noted with all three of these fullerene derivatives when their concentrations were 
lowered to 0.001 μM, and, with Gd3N@C80–OH, at concentrations as low as 0.001 nM (data not 
shown). These concentrations are sufficiently lower than the paraoxon concentration that 
adsorption of the OP compound appears unlikely to be responsible for the fullerene effect. 
4. Discussion 
The present study screened eight derivatized fullerenes for their ability to protect human 
neuroblastoma cells and hen brain homogenates from paraoxon- and DFP-induced AChE 
inhibition in vitro. All showed protective capability, being more effective when paraoxon and 
DFP concentrations were not at the highest concentrations tested. Given that the fullerene 
derivatives tested were effective, although at lower concentrations of paraoxon and DFP, and 
that they had no detrimental effects on cells, they may serve as a platform for developing next 
generation compounds that protect against OP exposure. 
The in vitro studies described here suggest that the derivatized fullerenes would be safe as no 
cytotoxicity was observed at concentrations that were protective. As expected (because they are 
not hardy cancer cells), the primary neuronal cells were more sensitive to a detrimental effect of 
the fullerene derivatives (reduced ATP production) than the neuroblastoma cells. Our results are 
consistent with those that demonstrated no toxicity to human leukocytes, keratinocytes, or bovine 
alveolar cells using water soluble, well characterized and purified fullerene preparations 
( Kolosnjaj et al., 2007). Water solubility, particle size, and surface charge all affect cytotoxicity 
( Johnson et al., 2010). 
Derivatized fullerenes have previously been reported to have free radical scavenging 
(antioxidant) capability, including restorative effects on protective enzymes and glutathione 
(Iezzi et al., 2002, Johnson et al., 2010,Lee et al., 2002, Olmstead et al., 2001, Wang et al., 
1999 and Yin et al., 2006). This observation was confirmed with the eight test compounds used 
in these studies, as all demonstrated concentration-related capability to scavenge free radicals 
produced in a xanthine/xanthine oxidase system. This in vitro system used here is biologically 
relevant as subsequent production of reactive oxygen species, including peroxides and nitric 
oxides, can lead to cell injury. Given that evidence of oxidative stress induced by exposure to OP 
compounds (e.g., depletion of extracelluar redox substances such glutathione) has appeared in 
the literature ( Jett and Narova, 2000, Pazdernik et al., 2001, Pena-Llopis et al., 2005 and Qiao et 
al., 2005), fullerenes could scavenge the OP products that deplete these substances. This property 
could reduce the deleterious effects of OP compounds that extend beyond acetylcholinesterase 
inhibition. Therefore, fullerene derivatives are potentially an attractive tool for counteracting 
some of the deleterious effect of these toxicants. 
Although direct association between AChE inhibition and free radical production cannot be 
made with the test system used here, the derivatized fullerene test compounds were protective. 
Their ability to scavenge the OP compound itself, as reported for another type of nanomaterial 
(Newman et al., 2007) could have been a contributor, as this would limit both OP-induced AChE 
inhibition and production of substances associated with oxidative stress. 
The possible effectiveness of derivatized fullerenes in protecting from toxicity that follows 
significant exposure to AChE-inhibiting OP compounds is of interest. Reports suggest fullerene 
derivatives similar to those used in the present experiments can be administered to rodents, 
protecting them from damage to the nervous system, without evidence of detrimental effects 
(Dugan et al., 1997, Dugan et al., 2001, Gharbi et al., 2005, Johnson et al., 2010, Quick et al., 
2008, Wang et al., 2006 and Yamago et al., 1995). Like oximes (Shrot et al., 2009), the 
protective effect on the nervous system occurs even though the brain is not the organ receiving 
the highest concentrations of fullerenes after systemic administration (Wang et al., 
2006 and Yamago et al., 1995). We have also demonstrated that fullerene derivatives are potent 
anti-inflammatories and the efficacy critically depends on the moieties added to the carbon cage 
(Dellinger et al., 2009 and Ryan et al., 2007). Potential usefulness of derivatized fullerenes in 
reducing the risk of OP-induced toxicities deserves investigation. This is because the most 
effective treatment of the cholinergic poisoning OP compounds induce (atropine) is not given 
before clinical evidence appears because the treatment itself can be toxic at its antidotal dosage 
(Taylor, 2006). In contrast, the apparent safety of derivatized fullerene derivatives may allow 
them to be used after exposure but before clinical signs of toxicity appear. 
It is not appropriate to extrapolate these in vitro results to situations in which humans and 
animals may need protection from potent, direct-acting AChE inhibitors such as the potent OP 
agents that provide chemical threats or their surrogates used here ( Ehrich and Dorman, 2004). 
Pharmacokinetics parameters relevant to whole animal exposures are difficult to impossible to 
study using cultured cells or tissue homogenates. Absorption, metabolism and excretion of toxic 
agents such as the OP compounds takes place in vivo, but not in the incubates used here. Of 
particular concern is the ability of proposed amelioration agents to reach the OP compound 
before it gets into the nervous system, or the ability to interact with the enzymatic target of the 
OP compound within the nervous system. Lipophilicity may be a contributing factor as 
derivatized fullerenes cross the blood–brain barrier; fullerenes examined here have partition 
coefficients similar to those used in published distribution studies ( Yamago et al., 1995). For the 
present studies, the fullerene derivatives were incubated with the paraoxon or DFP before the 
cells were exposed to these AChE inhibitors because direct exposure results in extremely rapid 
covalent binding of the OP compound to the enzyme (Taylor, 2006). Such in vitro studies 
allowed for examination of multiple compounds and multiple parameters with high efficiency. 
These studies provide proof-of-concept that derivatized fullerenes may be used as new agents to 
counteract the effects of OP exposure. Further studies on next generation fullerene derivatives 
are warranted to identify lead candidates for further in vivo studies. 
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